Mirati Therapeutics Gets $65M In Deal With China's Zai Lab :

Mirati Therapeutics Gets $65M In Deal With China's Zai Lab


socaltech.com
San Diego-based oncology therapeutics developer
Mirati Therapeutics said this morning that it has received $65M in an upfront payment, as part of a deal with Chinese company
Zai Lab. According to the to companies,t he two have entered into a collaboration to develop and commercialize Mirati's Adagrasib in Greater China. Mirati will receive $65M upfront, with up to approximately $273M in potential milestone payments and royalties. Charles M. Baum, M.D., Ph.D., is President and CEO of Mirati Therapeutics. The company's cancer treatment is aimed at treating patients with the KRASG12C mutation.

Related Keywords

China , Chinese , Mirati Adagrasib , Charlesm Baum , M In Deal With China Zai Lab , Zai Lab , Therapeutics Gets , Deal With China , Mirati Therapeutics , Emiraty , Herapeutics , Biotech , Lifescience , Nailab , Ai , Lab , Nternational , Dancer , Iosciences , , சீனா , சீன , ஜா ஆய்வகம் , சிகிச்சை பெறுகிறது , ஒப்பந்தம் உடன் சீனா , மிரட்டி சிகிச்சை , இோதேச் , ஐ , அப , ஹினா ,

© 2025 Vimarsana